ArticleBMC gastroenterology2025
Machine learning for predicting all-cause mortality of metabolic dysfunction-associated fatty liver disease: a longitudinal study based on NHANES.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Evaluation methods of hepatic steatosis: From conventional techniques to emerging biomarkers.World journal of hepatology · 2026Review
- Predicting the risk of metabolic-associated fatty liver disease in the elderly population in China: construction and evaluation of interpretable machine learning models.Frontiers in medicine · 2025Article
- Hybrid intelligent systems for liver disease prediction: a demographic-aware machine learning framework.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe mortality burden of metabolic dysfunction-associated fatty liver disease (MAFLD) is rising, making it crucial to predict mortality and identify the factors influencing it. While advanced machine learning algorithms are gaining recognition as effective tools for clinical prediction, their ability to predict all-cause mortality of MAFLD individuals remains uncertain. This study aimed to develop different machine learning models to predict all-cause mortality of MAFLD individuals, compare the predictive performance of these models, and identify the risk factors contributing all-cause mortality, which is crucial for management of MAFLD individuals.
methodsWe included 3921 MAFLD individuals in NHANES III. After a median follow-up time of 310 months, 1815 (46.3%) deaths were recorded. The data (demographic, behavioral factors and laboratory indicators) were utilized to construct machine learning models (Coxnet, RSF, GBS) after feature selection. Time-dependent AUC, time-dependent brier and C-index were then evaluated the performance of models. We identified the top five factors that contributed significantly to all-cause mortality and further explore the association with all-cause mortality using RCS and Kaplan-Meier survival curves.
resultsCoxnet showed the best performance in short-term and long-term predictions with time-dependent AUC of 0.82 at 5 years and 0.88 at 25 years. Age, FORNS, waist circumstance, AAR, FLI were associated positively with all-cause mortality. Compared to the individuals who smoked more than 100 cigarettes, those below 100 had better survival outcome (P < 0.0001).
conclusionsMachine learning has a promising application in predicting all-cause mortality in MAFLD individuals. Combined the results of interpretable machine learning and association analyses, we found risk factors which contributing to the all-cause mortality. These findings provide insights for community health practitioners to intervene in modifiable risk factors, thereby improving the survival and quality of life of MAFLD individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.